NATCAPSUQBSENATURAL CAPSULES LIMITEDMediumNeutral
Announced Thu, 13 Aug · 01:01 IST

Natural Capsules Q1FY27: Revenue Rs 48.71 Cr, PAT Loss Rs 5.74 Cr

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing

NATCAPSUQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.0%1-day move
₹158.11
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.0-6.2-6.9-5.4-4.4
Up moveDown movePending
AI summary

Natural Capsules Q1FY27: Revenue Rs 48.71 Cr (down 17 percent QoQ, up 8 percent YoY). EBITDA rose to Rs 1.12 Cr with margins at 2.30 percent (up 251 percent YoY). PAT remained a loss of Rs 5.74 Cr on high finance costs. MD cited ERP transition disruption in last 5 days of quarter. Capsule margins held up via cost pass-throughs; firm converting HPMC lines to gelatine on erratic US demand. API arm commenced Fermbox Bio contract manufacturing and signed a new Mumbai client; first backward-integrated prednisolone batch expected by end of September.

Likely market impact

Mixed signals - capsule margins improving but persistent PAT losses and elevated finance costs continue to weigh. API scaling and new CMO deals remain key monitorables.